Clinical Trial Applications: Filter, Search, and view applications


Clear
Extended search...

Page 67 of 114, showing 5 Applications out of 567 total, starting on record 331, ending on 335

# Protocol No Study Title Investigator(s) & Site(s)

331.

ECCT/23/10/06   CONSTELLATION
    A Phase 3, randomized, double-blind, placebo-controlled study to evaluate the effect of Bi-26 (strain of Bifidobacterium longum, B. infantis) supplementation versus placebo on weight gain in underweight infants   
Principal Investigator(s)
1. Dr Godfrey Allan Otieno
2. Dr Videlis Nduba
Site(s) in Kenya
1. KEMRI-Kondele Children’s Hospital (Kisumu county)
2. KEMRI CRDR Clinical Research Annex (Nairobi City county)
 
View

332.

ECCT/23/12/03   CONSTELLATION
    A Phase 3, randomized, double-blind, placebo-controlled study to evaluate the effect of Bi-26 (strain of Bifidobacterium longum, B. infantis) supplementation versus placebo on weight gain in underweight infants   
Principal Investigator(s)
1. Dr Benson Ochieng Singa
Site(s) in Kenya
1. Migori County Referral Hospital (Migori county)
 
View

333.

ECCT/25/11/01   COMBO-CONSTELLATION
    A Phase 3, randomized, double-blind, placebo-controlled trial to evaluate the effect of Bifidobacterium longum subsp. infantis DSM33361(Bifin02) administered together with Lacticaseibacillus rhamnosus GG DSM33156 (LGG®) versus placebo on weight gain in underweight infants   
Principal Investigator(s)
1. Dr. Wilson Muraya
Site(s) in Kenya
1. KENYA MEDICAL RESEARCH INSTITUTE- MTWAPA (Kilifi county)
2. Moi University Clinical Research Centre-MUCRU (Uasin Gishu county)
3. Kenya Medical Research Institute (KEMRI) CRDR (Nairobi City county)
 
View

334.

ECCT/15/06/03   DolutegrAvir With NRTIs as second-line treatment (DAWNING)
    A Phase 3b, randomised, open-label study of the antiviral activity and safety of dolutegravir compared to lopinavir/ritonavir both administered with dual nucleoside reverse transcriptase inhibitor therapy in HIV-1 infected adult subjects with treatment failure on first line therapy   
Principal Investigator(s)
1. Dr. Evans Inyangala Amukoye
2. Dr. Maricianah Atieno Onono
Site(s) in Kenya
1. Center for Respiratory Diseases Research, CRDR, KEMRI, Nairobi (Nairobi City county)
2. KEMRI-Research Care and Training Program (RCTP), Family AIDS Care and Education Services (FACES), Lumumba health centre (Kisumu county)
 
View

335.

ECCT/21/07/05   CARES
    A Phase 3b, Randomized, Multicenter, Open-Label Study Evaluating the Efficacy, Safety, and Tolerability of Switching to Long-Acting Cabotegravir Plus Long-Acting Rilpivirine from Current Antiretroviral Regimen in HIV-1 Infected, Virologically Suppressed Adults in Sub-Saharan Africa       
Principal Investigator(s)
1. Dr Reena Shah
Site(s) in Kenya
1. Aga Khan University Hospital Nairobi (Nairobi City county)
2. KEMRI Walter Reed Project (Kericho county)
3. Moi University Clinical Research Centre (Uasin Gishu county)
 
View